Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016


  • Products Id :- GMDHC8456IDB
  • |
  • Pages: 212
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

- The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects

- The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 9

Therapeutics Development 10

Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 10

Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 11

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 12

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 15

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 20

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25

Aeolus Pharmaceuticals, Inc. 25

Angion Biomedica Corp. 26

Atox Bio Ltd. 27

BCN Biosciences L.L.C. 28

Bolder Biotechnology, Inc. 29

Cellerant Therapeutics, Inc. 30

Cellphire, Inc. 31

Chrysalis BioTherapeutics, Inc. 32

Cleveland BioLabs, Inc. 33

Cumberland Pharmaceuticals, Inc. 34

Diffusion Pharmaceuticals Inc. 35

GNI Group Ltd. 36

Humanetics Corporation 37

INSYS Therapeutics, Inc. 38

Meabco A/S 39

Neumedicines Inc. 40

Nohla Therapeutics Inc. 41

Onconova Therapeutics, Inc. 42

Original BioMedicals Co. Ltd. 43

PharmaIN Corporation 44

Pluristem Therapeutics Inc. 45

RDD Pharma Ltd. 46

Reata Pharmaceuticals, Inc. 47

RedHill Biopharma Ltd. 48

RxBio, Inc. 49

SK Chemicals Co., Ltd. 50

Soligenix, Inc. 51

Stemedica Cell Technologies, Inc. 52

Terapio Corporation 53

Tonix Pharmaceuticals Holding Corp. 54

Vida Therapeutics Inc. 55

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 60

Assessment by Route of Administration 63

Assessment by Molecule Type 65

Drug Profiles 67

A-02 - Drug Profile 67

AB-103 - Drug Profile 68

ABC-294640 - Drug Profile 71

AEOL-10150 - Drug Profile 76

AEOL-10171 - Drug Profile 85

amifostine - Drug Profile 86

Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile 87

AVMOC-001 - Drug Profile 88

BB-3 - Drug Profile 89

BBT-007 - Drug Profile 92

BBT-015 - Drug Profile 93

BBT-018 - Drug Profile 94

BBT-059 - Drug Profile 95

BCN-057 - Drug Profile 96

BIO-300 - Drug Profile 97

BMX-001 - Drug Profile 100

BPC-2 - Drug Profile 101

C-2E2 - Drug Profile 102

C-2E5 - Drug Profile 103

Cell Therapy for Acute Radiation Syndrome - Drug Profile 104

cerium oxide - Drug Profile 105

CLT-009 - Drug Profile 106

Des-Asp Angiotensin 1 - Drug Profile 107

Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 108

entolimod - Drug Profile 109

EWA-001 - Drug Profile 116

HSJ-0017 - Drug Profile 117

JP4-039 - Drug Profile 118

LGM-2605 - Drug Profile 120

m-2A2 - Drug Profile 121

molgramostim - Drug Profile 122

monosodium luminol - Drug Profile 123

NMIL-121 - Drug Profile 125

omaveloxolone - Drug Profile 128

ondansetron hydrochloride - Drug Profile 131

ondansetron hydrochloride CR - Drug Profile 132

Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile 137

pirfenidone - Drug Profile 138

PLXR-18 - Drug Profile 140

RDD-2007 - Drug Profile 146

recilisib sodium - Drug Profile 147

Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 149

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 150

Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 151

Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 152

RES-529 - Drug Profile 153

RP-239X - Drug Profile 157

rusalatide acetate - Drug Profile 158

Rx-100 - Drug Profile 161

SGX-201 - Drug Profile 163

SGX-202 - Drug Profile 164

SKI-2162 - Drug Profile 167

Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile 168

Small Molecules for Radiation and Chemical Toxicity - Drug Profile 169

Small Molecules for Radiation Toxicity - Drug Profile 170

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 171

ST-266 - Drug Profile 172

ST-7 - Drug Profile 174

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 175

SY-303A - Drug Profile 181

SY-513 - Drug Profile 182

SYGN-305 - Drug Profile 183

SYGN-399 - Drug Profile 184

Thrombosomes - Drug Profile 185

TPO-7630 - Drug Profile 186

TPO-7640 - Drug Profile 187

VEDA-1209 - Drug Profile 188

VTI-1000 Series - Drug Profile 189

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 190

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 195

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 196

Featured News & Press Releases 196

Appendix 206

Methodology 206

Coverage 206

Secondary Research 206

Primary Research 206

Expert Panel Validation 206

Contact Us 206

Disclaimer 207

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016 15

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 61

Number of Products by Top 10 Targets, H2 2016 62

Number of Products by Stage and Top 10 Targets, H2 2016 62

Number of Products by Top 10 Mechanism of Actions, H2 2016 65

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 65

Number of Products by Top 10 Routes of Administration, H2 2016 68

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 68

Number of Products by Top 10 Molecule Types, H2 2016 70

Number of Products by Stage and Top 10 Molecule Types, H2 2016 70

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016 15

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Comparative Analysis by Unknown Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 30

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2016 31

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd., H2 2016 32

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences L.L.C., H2 2016 33

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2016 34

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2016 35

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H2 2016 36

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 37

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2016 38

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016 39

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 40

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H2 2016 41

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2016 42

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H2 2016 43

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2016 44

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2016 45

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc., H2 2016 46

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2016 47

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co. Ltd., H2 2016 48

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H2 2016 49

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2016 50

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H2 2016 51

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 52

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H2 2016 53

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2016 54

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co., Ltd., H2 2016 55

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2016 56

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 57

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2016 58

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 59

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Vida Therapeutics Inc., H2 2016 60

Assessment by Monotherapy Products, H2 2016 61

Number of Products by Stage and Target, H2 2016 63

Number of Products by Stage and Mechanism of Action, H2 2016 66

Number of Products by Stage and Route of Administration, H2 2016 69

Number of Products by Stage and Molecule Type, H2 2016 71

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2016 195

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H2 2016 196

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H2 2016 197

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H2 2016 198

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..4), H2 2016 199

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2016 200

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aeolus Pharmaceuticals, Inc.

Angion Biomedica Corp.

Atox Bio Ltd.

BCN Biosciences L.L.C.

Bolder Biotechnology, Inc.

Cellerant Therapeutics, Inc.

Cellphire, Inc.

Chrysalis BioTherapeutics, Inc.

Cleveland BioLabs, Inc.

Cumberland Pharmaceuticals, Inc.

Diffusion Pharmaceuticals Inc.

GNI Group Ltd.

Humanetics Corporation

INSYS Therapeutics, Inc.

Meabco A/S

Neumedicines Inc.

Nohla Therapeutics Inc.

Onconova Therapeutics, Inc.

Original BioMedicals Co. Ltd.

PharmaIN Corporation

Pluristem Therapeutics Inc.

RDD Pharma Ltd.

Reata Pharmaceuticals, Inc.

RedHill Biopharma Ltd.

RxBio, Inc.

SK Chemicals Co., Ltd.

Soligenix, Inc.

Stemedica Cell Technologies, Inc.

Terapio Corporation

Tonix Pharmaceuticals Holding Corp.

Vida Therapeutics Inc.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Products under Development, Key Players in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Overview, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Assessment

select a license

Single User License
USD 2000 INR 128960
Site License
USD 4000 INR 257920
Corporate User License
USD 6000 INR 386880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com